Do You Qualify for Voydeya (danicopan) Coverage by Blue Cross Blue Shield in New York? Decision Tree & Next Steps

Answer Box: Your Fastest Path to Voydeya Coverage

If you have paroxysmal nocturnal hemoglobinuria (PNH) with extravascular hemolysis despite C5 inhibitor therapy, you likely qualify for Voydeya (danicopan) coverage through Blue Cross Blue Shield in New York. The fastest approval path requires: (1) Current C5 inhibitor therapy (Soliris/Ultomiris), (2) Evidence of ongoing hemolysis (hemoglobin ≤9.5 g/dL and reticulocyte count ≥120 × 10⁹/L), and (3) Complete REMS vaccination requirements. First step today: Contact your hematologist to initiate the VOYDEYA REMS program enrollment and gather your recent lab results showing extravascular hemolysis markers.

Table of Contents

  1. How to Use This Guide
  2. Eligibility Triage: Do You Qualify?
  3. If "Likely Eligible": Document Checklist
  4. If "Possibly Eligible": Tests to Request
  5. If "Not Yet": Alternative Approaches
  6. If Denied: Appeal Path Chooser
  7. New York External Appeals: Your Safety Net
  8. Resources & Next Steps

How to Use This Guide

This decision tree helps patients and clinicians determine the best path forward for Voydeya coverage through Blue Cross Blue Shield plans in New York. Start with the eligibility triage below to understand where you stand, then follow the specific action steps for your situation.

Note: Blue Cross Blue Shield operates through 33 independent plans. While this guide covers general BCBS policies, always verify specific requirements with your local New York plan.

Eligibility Triage: Do You Qualify?

Primary Requirements Checklist

Answer these questions to determine your eligibility tier:

Diagnosis confirmed?

  • PNH diagnosed by flow cytometry showing GPI-deficient cells
  • ICD-10 code D59.5 documented in medical records

Currently on C5 inhibitor therapy?

  • Stable on Soliris (eculizumab) OR Ultomiris (ravulizumab) for ≥6 months
  • No plans to discontinue C5 inhibitor (Voydeya is add-on only, never monotherapy)

Evidence of extravascular hemolysis despite C5 therapy?

  • Hemoglobin ≤9.5 g/dL AND absolute reticulocyte count ≥120 × 10⁹/L
  • Ongoing transfusion requirements or persistent anemia symptoms

Prescriber qualified?

Vaccination requirements met?

  • Meningococcal (A, C, W, Y, B), pneumococcal, and Hib vaccines current
  • Administered ≥2 weeks before planned Voydeya start date

Your Eligibility Result

If you answered YES to all 5 questions: → Likely Eligible - Proceed to document checklist If you answered YES to 3-4 questions: → Possibly Eligible - Additional testing needed
If you answered YES to ≤2 questions: → Not Yet - Consider alternatives first

If "Likely Eligible": Document Checklist

Required Documentation Package

Document Type What to Include Where to Find It
PNH Confirmation Flow cytometry report, ICD-10 D59.5 diagnosis Hematologist records
C5 Inhibitor History 6+ months treatment records, current dosing Infusion center logs
Extravascular Hemolysis Labs Hemoglobin, reticulocyte count, LDH, bilirubin Recent lab results (≤30 days)
REMS Documentation Prescriber enrollment, vaccination records VOYDEYA REMS portal
Medical Necessity Letter Hematologist attestation of need Provider documentation

Submission Path: Step-by-Step

Step 1: REMS Enrollment (1-2 days)

  • Prescriber enrolls at voydeyarems.com
  • Verify vaccination status; administer if needed ≥2 weeks before treatment

Step 2: Prior Authorization Submission (Same day)

  • Submit via Blue Cross provider portal or fax
  • Include complete document package above
  • Request expedited review if medically urgent

Step 3: Follow-Up (5-10 days)

  • Standard review: 5-14 business days
  • Expedited review: 24-48 hours for urgent cases
  • Track status via provider portal
From our advocates: Patients who submit complete documentation packages with clear evidence of extravascular hemolysis markers typically see faster approvals. Having your hematologist highlight the specific lab values that meet coverage criteria can make the difference between a quick approval and additional information requests.

If "Possibly Eligible": Tests to Request

Missing Documentation to Gather

If missing recent labs, request:

  • Complete blood count with reticulocyte count
  • Comprehensive metabolic panel
  • LDH, total/direct bilirubin, haptoglobin
  • Flow cytometry confirmation (if >1 year old)

If C5 inhibitor history incomplete, obtain:

  • Infusion records showing consistent therapy
  • Documentation of any dose adjustments
  • Evidence of intravascular hemolysis control

Timeline to re-apply: 2-4 weeks after obtaining missing documentation

What to Track While Waiting

Monitor symptoms that support medical necessity:

  • Transfusion requirements
  • Fatigue scores or functional assessments
  • Breakthrough hemolysis episodes
  • Quality of life impacts

If "Not Yet": Alternative Approaches

Prepare for Exception Requests

If not on C5 inhibitor:

  • Discuss starting Soliris or Ultomiris first
  • Document any contraindications to C5 therapy
  • Consider clinical trial options

If hemolysis markers don't meet thresholds:

  • Track trends over time (may worsen)
  • Document functional impacts and symptoms
  • Gather evidence of transfusion burden

Alternative therapies to discuss:

  • Fabhalta (iptacopan) - oral Factor B inhibitor
  • Empaveli (pegcetacoplan) - C3 inhibitor option
  • Optimized C5 inhibitor dosing

If Denied: Appeal Path Chooser

Blue Cross Blue Shield Internal Appeals

Level 1: Standard Internal Appeal

  • Deadline: 180 days from denial notice
  • Processing time: 30 days standard, 72 hours expedited
  • Required documents: Denial letter, additional medical evidence, physician letter

When to request expedited review:

  • Serious health risk from treatment delay
  • Physician attestation of urgent medical need
  • Documented clinical deterioration

Common Denial Reasons & Fixes

Denial Code Reason How to Overturn
Medical Necessity Insufficient evidence of EVH Submit recent labs showing Hgb ≤9.5 + retic count ≥120 × 10⁹/L
Step Therapy Must try alternatives first Document C5 inhibitor therapy ≥6 months, contraindications to other agents
REMS Requirements Missing vaccination/enrollment Complete REMS enrollment, submit vaccination records
Non-Formulary Drug not on formulary Request formulary exception with medical necessity documentation

Peer-to-Peer Review Strategy

Before formal appeal, request peer-to-peer review:

  • Hematologist discusses case directly with Blue Cross medical director
  • Often resolves denials faster than formal appeals
  • No additional paperwork required

New York External Appeals: Your Safety Net

New York provides strong consumer protections through the Department of Financial Services External Appeal program.

When External Appeals Apply

Eligible denial types:

  • "Not medically necessary" determinations
  • "Experimental/investigational" designations
  • Out-of-network coverage disputes

Filing Process & Timelines

Appeal Type Filing Deadline Processing Time Best For
Standard External 4 months from internal denial 30 days Non-urgent cases
Expedited External 4 months from internal denial 72 hours Serious health risk
Urgent Drug Appeal 4 months from internal denial 24 hours Rare disease emergencies

How to file:

  1. Complete DFS External Appeal form
  2. Include patient consent, denial notice, supporting medical evidence
  3. Submit online via DFS Portal (preferred)
  4. Pay $25 fee (waived for financial hardship, refunded if you win)

For help filing: Contact Community Health Advocates at 888-614-5400 for free assistance.

Important: External appeal decisions are binding on Blue Cross Blue Shield. If you win, they must cover the treatment and refund your filing fee.

Resources & Next Steps

Essential Contacts & Forms

Blue Cross Blue Shield New York:

  • Member services: Check your insurance card for plan-specific number
  • Provider portal: Verify current PA submission process
  • Appeals: Submit via member portal or certified mail

New York State Resources:

REMS Program:

Coverage Assistance Programs

Manufacturer Support:

  • Alexion patient services: Check voydeya.com for copay assistance
  • Prior authorization support through manufacturer

Foundation Grants:

  • PAN Foundation: Paroxysmal Nocturnal Hemoglobinuria fund
  • NORD Patient Assistance: Premium and copay support programs

Counterforce Health helps patients, clinicians, and specialty pharmacies turn insurance denials into targeted, evidence-backed appeals. Their platform analyzes denial letters and plan policies to draft point-by-point rebuttals aligned to each payer's specific requirements, pulling the right clinical evidence and procedural details to maximize approval chances.

Checklist: What to Gather Before You Start

Before initiating your Voydeya prior authorization, collect:

  • Insurance card with member/group numbers
  • Complete PNH diagnosis records (flow cytometry)
  • C5 inhibitor treatment history (≥6 months)
  • Recent labs showing extravascular hemolysis markers
  • Vaccination records (meningococcal, pneumococcal, Hib)
  • Hematologist contact information and NPI number
  • Prior therapy documentation (failures, contraindications)

Timeline expectations: Complete applications typically receive decisions within 5-14 business days. Incomplete submissions may take 30+ days due to additional information requests.

For complex cases or if you've experienced multiple denials, Counterforce Health specializes in crafting comprehensive appeals that address payer-specific criteria and maximize approval odds through targeted medical evidence and proper procedural compliance.

Sources & Further Reading


Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions vary by individual plan and clinical circumstances. Always consult with your healthcare provider and insurance plan directly for personalized guidance. For questions about New York insurance regulations, contact the Department of Financial Services at (800) 342-3736.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.